A cost-effectiveness analysis of empagliflozin for heart failure patients across the full spectrum of ejection fraction in Spain: combined results of the EMPEROR-Preserved and EMPEROR-Reduced trials.

Xavier García-MollFrancesco CrociAlexandra SoléElisabeth S Hartgers-GubbelsMiguel A Calleja-Hernández

Published in: Expert review of cardiovascular therapy (2024)

Empagliflozin is the first treatment with established efficacy and cost-effectiveness for HF patients across EF from the perspective of healthcare payers in Spain. Empagliflozin also proved to be cost-effective for all subgroups of patients included in the analysis.

Keyphrases

ejection fraction
aortic stenosis
end stage renal disease
healthcare
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
heart failure
coronary artery disease
replacement therapy